Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis

NCT06456580 is registered in ClinicalTrials.gov with Vor Biopharma as lead sponsor.

NCT NCT06456580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06456580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis
Lead sponsor
Vor Biopharma
Phase
Phase 3
Overall status
Recruiting
Start date
July 17, 2024
Completion date
January 31, 2029
Enrollment
180 (estimated)
Sites
111

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis